| 2014 | Article | Ouattara E., Ross EL.,Yazdanpanah Y., Wong A.Y., Robine M., Losina E., Moh R., Walensky RP., Danel C, Paltiel A. D., Eholié SP., Freedberg KA., Anglaret X. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: A model-based analysis in Côte d’Ivoire. JAIDS 2014, In press |
| 2013 | Article | Messou E, Chaix ML, Gabillard D, Yapo V, Toni TD, Minga A, Kouakou MG, Ouattara E, Rouzioux C, Danel C, Eholie SP, Anglaret X.. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: The VOLTART cohort study in Côte d’Ivoire, West Africa. J Acquir Immune Defic Syndr. 2013 Jun 21. [Epub ahead of print] |
| 2013 | Article | Ouattara E, Danel C, Gabillard D, Moh R, Peytavin G, Konan R, Le Carrou J, Karcher S, Eholie SP, Anglaret X. Early upper digestive side effects of tenofovir/emtricitabine +zidovudine in West African adults with high CD4 counts. JIAS 2013 Apr30 16:18059 |
| 2012 | Article | Ouattara E, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, Walensky RP, Freedberg KA. Projecting the clinical benefits and risks of using efavirenz containing antiretroviral therapy regimens in women of childbearing age. AIDS. 2012 Mar13;26 (5):625-34 |
| 2012 | Article | Anglaret X, Scott C, Walensky R, Ouattara E, Losina E, Moh R, Becker JE, Uhler L, Danel C, Messou E, Eholie SP, Freedberg KA. Could Early Antiretroviral Therapy Entail More Risks than Benefits in sub-Saharan African HIV-Infected Adults? A Model-Based Analysis Antivir Ther 2012; In press |
| 2011 | Article | Ekouevi DK, Coffie P, Ouattara E, Moh R, Amani-Bosse C, Messou E, Sissoko M, Anglaret X, Eholie SP, Danel C, Dabis F. Pregnancy Outcomes in Women Exposed to Efavirenz and Nevirapine: An Appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d’Ivoire. J Acquir Immune Defic Syndr 2011;56: 183-187 |
